http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29774767

Outgoing Links

Predicate Object
contentType Comparative Study|Journal Article
endingPage 643
issn 1173-2563
1179-1918
issueIdentifier 7
pageRange 629-643
publicationName Clinical Drug Investigation
startingPage 629
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1d33dbd06de50e8e836027ea8a1f4aeb
bibliographicCitation Bensimon AG, Zhou Z, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. Clinical Drug Investigation. 2020 May 16;40(7):629–43. doi: 10.1007/s40261-020-00922-6.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_332dddfd39339f90d5968df7ef4437f4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e83f37fad3faddd57d25f3ad10d54005
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_035d18135e405d2bec02d1237c39e513
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3839-6966
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86640082a6c7c8995f5d3af887c0f011
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e96bd3fcddedb3079444198c7fb0b698
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb530bad5ad88764ee0c10914aa739ce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05110da2b46d93d6f636169e4d709060
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3dc580213e6c51006305c0f25d54dae
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_390c9741325fd890b112950b7635ce7d
date 2020-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/32418051
https://pubmed.ncbi.nlm.nih.gov/PMC7311503
https://doi.org/10.1007/s40261-020-00922-6
isPartOf https://portal.issn.org/resource/ISSN/1173-2563
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33140
https://portal.issn.org/resource/ISSN/1179-1918
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
discusses http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0586473
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11707110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44462760
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1c50845b337a3c11fa194521642a3ec8

Total number of triples: 39.